nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP3A4—Ifosfamide—testicular cancer	0.0771	0.218	CbGbCtD
Palonosetron—CYP1A2—Etoposide—testicular cancer	0.0703	0.199	CbGbCtD
Palonosetron—CYP2D6—Vinblastine—testicular cancer	0.0643	0.182	CbGbCtD
Palonosetron—CYP3A4—Vinblastine—testicular cancer	0.0409	0.116	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—testicular cancer	0.0395	0.112	CbGbCtD
Palonosetron—CYP3A4—Etoposide—testicular cancer	0.0368	0.104	CbGbCtD
Palonosetron—CYP3A4—Doxorubicin—testicular cancer	0.0251	0.071	CbGbCtD
Palonosetron—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00108	0.00167	CcSEcCtD
Palonosetron—Discomfort—Etoposide—testicular cancer	0.00108	0.00167	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.00107	0.00166	CcSEcCtD
Palonosetron—Hypotension—Cisplatin—testicular cancer	0.00106	0.00165	CcSEcCtD
Palonosetron—Hypersensitivity—Dactinomycin—testicular cancer	0.00106	0.00165	CcSEcCtD
Palonosetron—Gastritis—Epirubicin—testicular cancer	0.00105	0.00163	CcSEcCtD
Palonosetron—Abdominal pain—Ifosfamide—testicular cancer	0.00104	0.00162	CcSEcCtD
Palonosetron—Body temperature increased—Ifosfamide—testicular cancer	0.00104	0.00162	CcSEcCtD
Palonosetron—Anaphylactic shock—Etoposide—testicular cancer	0.00104	0.00162	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00104	0.00161	CcSEcCtD
Palonosetron—Infection—Etoposide—testicular cancer	0.00104	0.00161	CcSEcCtD
Palonosetron—Abdominal distension—Epirubicin—testicular cancer	0.00104	0.0016	CcSEcCtD
Palonosetron—Asthenia—Dactinomycin—testicular cancer	0.00103	0.0016	CcSEcCtD
Palonosetron—Paraesthesia—Cisplatin—testicular cancer	0.00102	0.00158	CcSEcCtD
Palonosetron—Tachycardia—Etoposide—testicular cancer	0.00102	0.00158	CcSEcCtD
Palonosetron—Dyspnoea—Cisplatin—testicular cancer	0.00102	0.00157	CcSEcCtD
Palonosetron—Skin disorder—Etoposide—testicular cancer	0.00101	0.00157	CcSEcCtD
Palonosetron—Abdominal pain upper—Doxorubicin—testicular cancer	0.00101	0.00156	CcSEcCtD
Palonosetron—Hypokalaemia—Doxorubicin—testicular cancer	0.001	0.00155	CcSEcCtD
Palonosetron—Anorexia—Etoposide—testicular cancer	0.000995	0.00154	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000992	0.00154	CcSEcCtD
Palonosetron—Decreased appetite—Cisplatin—testicular cancer	0.000991	0.00153	CcSEcCtD
Palonosetron—Diarrhoea—Dactinomycin—testicular cancer	0.000987	0.00153	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000984	0.00152	CcSEcCtD
Palonosetron—Vomiting—Bleomycin—testicular cancer	0.000983	0.00152	CcSEcCtD
Palonosetron—Hypotension—Etoposide—testicular cancer	0.000975	0.00151	CcSEcCtD
Palonosetron—Rash—Bleomycin—testicular cancer	0.000975	0.00151	CcSEcCtD
Palonosetron—Gastritis—Doxorubicin—testicular cancer	0.000975	0.00151	CcSEcCtD
Palonosetron—Pain—Cisplatin—testicular cancer	0.000974	0.00151	CcSEcCtD
Palonosetron—Dermatitis—Bleomycin—testicular cancer	0.000974	0.00151	CcSEcCtD
Palonosetron—Hypersensitivity—Ifosfamide—testicular cancer	0.000974	0.00151	CcSEcCtD
Palonosetron—Abdominal distension—Doxorubicin—testicular cancer	0.000958	0.00148	CcSEcCtD
Palonosetron—Asthenia—Ifosfamide—testicular cancer	0.000948	0.00147	CcSEcCtD
Palonosetron—Paraesthesia—Etoposide—testicular cancer	0.000937	0.00145	CcSEcCtD
Palonosetron—Pruritus—Ifosfamide—testicular cancer	0.000935	0.00145	CcSEcCtD
Palonosetron—Dyspnoea—Etoposide—testicular cancer	0.000931	0.00144	CcSEcCtD
Palonosetron—Hyperglycaemia—Epirubicin—testicular cancer	0.000928	0.00144	CcSEcCtD
Palonosetron—Somnolence—Etoposide—testicular cancer	0.000928	0.00144	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—testicular cancer	0.000927	0.00144	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—testicular cancer	0.000925	0.00143	CcSEcCtD
Palonosetron—Nausea—Bleomycin—testicular cancer	0.000919	0.00142	CcSEcCtD
Palonosetron—Vomiting—Dactinomycin—testicular cancer	0.000917	0.00142	CcSEcCtD
Palonosetron—Rash—Dactinomycin—testicular cancer	0.000909	0.00141	CcSEcCtD
Palonosetron—Decreased appetite—Etoposide—testicular cancer	0.000907	0.0014	CcSEcCtD
Palonosetron—Diarrhoea—Ifosfamide—testicular cancer	0.000904	0.0014	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Etoposide—testicular cancer	0.000901	0.0014	CcSEcCtD
Palonosetron—Body temperature increased—Cisplatin—testicular cancer	0.000901	0.00139	CcSEcCtD
Palonosetron—Fatigue—Etoposide—testicular cancer	0.0009	0.00139	CcSEcCtD
Palonosetron—Pain—Etoposide—testicular cancer	0.000893	0.00138	CcSEcCtD
Palonosetron—Constipation—Etoposide—testicular cancer	0.000893	0.00138	CcSEcCtD
Palonosetron—Dizziness—Ifosfamide—testicular cancer	0.000874	0.00135	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—testicular cancer	0.000869	0.00135	CcSEcCtD
Palonosetron—Hepatobiliary disease—Epirubicin—testicular cancer	0.000868	0.00134	CcSEcCtD
Palonosetron—Epistaxis—Epirubicin—testicular cancer	0.000865	0.00134	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—testicular cancer	0.000863	0.00134	CcSEcCtD
Palonosetron—Sinusitis—Epirubicin—testicular cancer	0.000861	0.00133	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—testicular cancer	0.000859	0.00133	CcSEcCtD
Palonosetron—Nausea—Dactinomycin—testicular cancer	0.000857	0.00133	CcSEcCtD
Palonosetron—Gastrointestinal pain—Etoposide—testicular cancer	0.000854	0.00132	CcSEcCtD
Palonosetron—Vomiting—Ifosfamide—testicular cancer	0.00084	0.0013	CcSEcCtD
Palonosetron—Hypersensitivity—Cisplatin—testicular cancer	0.000839	0.0013	CcSEcCtD
Palonosetron—Bradycardia—Epirubicin—testicular cancer	0.000838	0.0013	CcSEcCtD
Palonosetron—Rash—Ifosfamide—testicular cancer	0.000833	0.00129	CcSEcCtD
Palonosetron—Dermatitis—Ifosfamide—testicular cancer	0.000833	0.00129	CcSEcCtD
Palonosetron—Abdominal pain—Etoposide—testicular cancer	0.000825	0.00128	CcSEcCtD
Palonosetron—Body temperature increased—Etoposide—testicular cancer	0.000825	0.00128	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—testicular cancer	0.000822	0.00127	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—testicular cancer	0.000821	0.00127	CcSEcCtD
Palonosetron—Asthenia—Cisplatin—testicular cancer	0.000818	0.00127	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—testicular cancer	0.000817	0.00126	CcSEcCtD
Palonosetron—Urinary tract disorder—Epirubicin—testicular cancer	0.000813	0.00126	CcSEcCtD
Palonosetron—Connective tissue disorder—Epirubicin—testicular cancer	0.000809	0.00125	CcSEcCtD
Palonosetron—Urethral disorder—Epirubicin—testicular cancer	0.000807	0.00125	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000803	0.00124	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—testicular cancer	0.000801	0.00124	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—testicular cancer	0.000798	0.00124	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—testicular cancer	0.000796	0.00123	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—testicular cancer	0.000795	0.00123	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—testicular cancer	0.000793	0.00123	CcSEcCtD
Palonosetron—Chills—Methotrexate—testicular cancer	0.00079	0.00122	CcSEcCtD
Palonosetron—Nausea—Ifosfamide—testicular cancer	0.000785	0.00122	CcSEcCtD
Palonosetron—Diarrhoea—Cisplatin—testicular cancer	0.00078	0.00121	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—testicular cancer	0.000778	0.0012	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—testicular cancer	0.000776	0.0012	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—testicular cancer	0.000771	0.00119	CcSEcCtD
Palonosetron—Eye disorder—Epirubicin—testicular cancer	0.00077	0.00119	CcSEcCtD
Palonosetron—Hypersensitivity—Etoposide—testicular cancer	0.000769	0.00119	CcSEcCtD
Palonosetron—Tinnitus—Epirubicin—testicular cancer	0.000768	0.00119	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—testicular cancer	0.000766	0.00119	CcSEcCtD
Palonosetron—Erythema—Methotrexate—testicular cancer	0.000766	0.00119	CcSEcCtD
Palonosetron—Cardiac disorder—Epirubicin—testicular cancer	0.000764	0.00118	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—testicular cancer	0.000753	0.00117	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—testicular cancer	0.00075	0.00116	CcSEcCtD
Palonosetron—Asthenia—Etoposide—testicular cancer	0.000749	0.00116	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—testicular cancer	0.000749	0.00116	CcSEcCtD
Palonosetron—Angiopathy—Epirubicin—testicular cancer	0.000747	0.00116	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—testicular cancer	0.000747	0.00116	CcSEcCtD
Palonosetron—Immune system disorder—Epirubicin—testicular cancer	0.000744	0.00115	CcSEcCtD
Palonosetron—Mediastinal disorder—Epirubicin—testicular cancer	0.000742	0.00115	CcSEcCtD
Palonosetron—Chills—Epirubicin—testicular cancer	0.000739	0.00114	CcSEcCtD
Palonosetron—Pruritus—Etoposide—testicular cancer	0.000739	0.00114	CcSEcCtD
Palonosetron—Arrhythmia—Epirubicin—testicular cancer	0.000736	0.00114	CcSEcCtD
Palonosetron—Alopecia—Epirubicin—testicular cancer	0.000728	0.00113	CcSEcCtD
Palonosetron—Vomiting—Cisplatin—testicular cancer	0.000724	0.00112	CcSEcCtD
Palonosetron—Mental disorder—Epirubicin—testicular cancer	0.000722	0.00112	CcSEcCtD
Palonosetron—Rash—Cisplatin—testicular cancer	0.000718	0.00111	CcSEcCtD
Palonosetron—Dermatitis—Cisplatin—testicular cancer	0.000718	0.00111	CcSEcCtD
Palonosetron—Erythema—Epirubicin—testicular cancer	0.000717	0.00111	CcSEcCtD
Palonosetron—Malnutrition—Epirubicin—testicular cancer	0.000717	0.00111	CcSEcCtD
Palonosetron—Diarrhoea—Etoposide—testicular cancer	0.000714	0.00111	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—testicular cancer	0.000712	0.0011	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—testicular cancer	0.000711	0.0011	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—testicular cancer	0.000708	0.0011	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—testicular cancer	0.000707	0.00109	CcSEcCtD
Palonosetron—Flatulence—Epirubicin—testicular cancer	0.000706	0.00109	CcSEcCtD
Palonosetron—Dysgeusia—Epirubicin—testicular cancer	0.000702	0.00109	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—testicular cancer	0.000691	0.00107	CcSEcCtD
Palonosetron—Dizziness—Etoposide—testicular cancer	0.00069	0.00107	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—testicular cancer	0.000688	0.00107	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—testicular cancer	0.000687	0.00106	CcSEcCtD
Palonosetron—Chills—Doxorubicin—testicular cancer	0.000684	0.00106	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—testicular cancer	0.000681	0.00105	CcSEcCtD
Palonosetron—Nausea—Cisplatin—testicular cancer	0.000677	0.00105	CcSEcCtD
Palonosetron—Alopecia—Doxorubicin—testicular cancer	0.000673	0.00104	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—testicular cancer	0.000668	0.00103	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—testicular cancer	0.000664	0.00103	CcSEcCtD
Palonosetron—Vomiting—Etoposide—testicular cancer	0.000664	0.00103	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—testicular cancer	0.000663	0.00103	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—testicular cancer	0.000663	0.00103	CcSEcCtD
Palonosetron—Anaemia—Epirubicin—testicular cancer	0.000663	0.00103	CcSEcCtD
Palonosetron—Rash—Etoposide—testicular cancer	0.000658	0.00102	CcSEcCtD
Palonosetron—Dermatitis—Etoposide—testicular cancer	0.000658	0.00102	CcSEcCtD
Palonosetron—Headache—Etoposide—testicular cancer	0.000654	0.00101	CcSEcCtD
Palonosetron—Flatulence—Doxorubicin—testicular cancer	0.000654	0.00101	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—testicular cancer	0.000652	0.00101	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—testicular cancer	0.000652	0.00101	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—testicular cancer	0.00065	0.00101	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000648	0.001	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—testicular cancer	0.000644	0.000998	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—testicular cancer	0.000625	0.000968	CcSEcCtD
Palonosetron—Convulsion—Epirubicin—testicular cancer	0.000621	0.000962	CcSEcCtD
Palonosetron—Infection—Methotrexate—testicular cancer	0.000621	0.000962	CcSEcCtD
Palonosetron—Nausea—Etoposide—testicular cancer	0.00062	0.00096	CcSEcCtD
Palonosetron—Hypertension—Epirubicin—testicular cancer	0.000619	0.000958	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—testicular cancer	0.000613	0.000949	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—testicular cancer	0.000613	0.000949	CcSEcCtD
Palonosetron—Myalgia—Epirubicin—testicular cancer	0.00061	0.000945	CcSEcCtD
Palonosetron—Arthralgia—Epirubicin—testicular cancer	0.00061	0.000945	CcSEcCtD
Palonosetron—Anxiety—Epirubicin—testicular cancer	0.000608	0.000942	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—testicular cancer	0.000607	0.00094	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000606	0.000938	CcSEcCtD
Palonosetron—Discomfort—Epirubicin—testicular cancer	0.000603	0.000934	CcSEcCtD
Palonosetron—Dry mouth—Epirubicin—testicular cancer	0.000597	0.000924	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—testicular cancer	0.000596	0.000923	CcSEcCtD
Palonosetron—Anaphylactic shock—Epirubicin—testicular cancer	0.000585	0.000906	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—testicular cancer	0.000584	0.000904	CcSEcCtD
Palonosetron—Infection—Epirubicin—testicular cancer	0.000581	0.0009	CcSEcCtD
Palonosetron—Shock—Epirubicin—testicular cancer	0.000576	0.000891	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—testicular cancer	0.000575	0.00089	CcSEcCtD
Palonosetron—Nervous system disorder—Epirubicin—testicular cancer	0.000574	0.000888	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—testicular cancer	0.000573	0.000887	CcSEcCtD
Palonosetron—Tachycardia—Epirubicin—testicular cancer	0.000571	0.000884	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00057	0.000882	CcSEcCtD
Palonosetron—Skin disorder—Epirubicin—testicular cancer	0.000568	0.00088	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—testicular cancer	0.000566	0.000875	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—testicular cancer	0.000565	0.000874	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—testicular cancer	0.000565	0.000874	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—testicular cancer	0.000563	0.000871	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—testicular cancer	0.000561	0.000869	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000561	0.000868	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—testicular cancer	0.000558	0.000864	CcSEcCtD
Palonosetron—Anorexia—Epirubicin—testicular cancer	0.000558	0.000863	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—testicular cancer	0.000557	0.000863	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—testicular cancer	0.000556	0.000861	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—testicular cancer	0.000552	0.000855	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—testicular cancer	0.00055	0.000852	CcSEcCtD
Palonosetron—Hypotension—Epirubicin—testicular cancer	0.000547	0.000846	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—testicular cancer	0.000544	0.000841	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—testicular cancer	0.000541	0.000838	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00054	0.000836	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—testicular cancer	0.000539	0.000835	CcSEcCtD
Palonosetron—Infection—Doxorubicin—testicular cancer	0.000538	0.000833	CcSEcCtD
Palonosetron—Pain—Methotrexate—testicular cancer	0.000535	0.000828	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000533	0.000825	CcSEcCtD
Palonosetron—Shock—Doxorubicin—testicular cancer	0.000533	0.000825	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—testicular cancer	0.000531	0.000822	CcSEcCtD
Palonosetron—Insomnia—Epirubicin—testicular cancer	0.000529	0.000819	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—testicular cancer	0.000528	0.000818	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—testicular cancer	0.000526	0.000814	CcSEcCtD
Palonosetron—Paraesthesia—Epirubicin—testicular cancer	0.000525	0.000813	CcSEcCtD
Palonosetron—Dyspnoea—Epirubicin—testicular cancer	0.000522	0.000808	CcSEcCtD
Palonosetron—Somnolence—Epirubicin—testicular cancer	0.00052	0.000805	CcSEcCtD
Palonosetron—Anorexia—Doxorubicin—testicular cancer	0.000516	0.000799	CcSEcCtD
Palonosetron—Dyspepsia—Epirubicin—testicular cancer	0.000515	0.000797	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—testicular cancer	0.000511	0.000792	CcSEcCtD
Palonosetron—Decreased appetite—Epirubicin—testicular cancer	0.000509	0.000787	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—testicular cancer	0.000506	0.000783	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000505	0.000782	CcSEcCtD
Palonosetron—Fatigue—Epirubicin—testicular cancer	0.000504	0.000781	CcSEcCtD
Palonosetron—Constipation—Epirubicin—testicular cancer	0.0005	0.000775	CcSEcCtD
Palonosetron—Pain—Epirubicin—testicular cancer	0.0005	0.000775	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—testicular cancer	0.000494	0.000765	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—testicular cancer	0.000494	0.000765	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000493	0.000764	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—testicular cancer	0.00049	0.000758	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—testicular cancer	0.000486	0.000753	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—testicular cancer	0.000483	0.000747	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—testicular cancer	0.000481	0.000745	CcSEcCtD
Palonosetron—Gastrointestinal pain—Epirubicin—testicular cancer	0.000478	0.000741	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—testicular cancer	0.000477	0.000738	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—testicular cancer	0.000471	0.000729	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000467	0.000724	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—testicular cancer	0.000467	0.000723	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—testicular cancer	0.000463	0.000717	CcSEcCtD
Palonosetron—Pain—Doxorubicin—testicular cancer	0.000463	0.000717	CcSEcCtD
Palonosetron—Body temperature increased—Epirubicin—testicular cancer	0.000463	0.000716	CcSEcCtD
Palonosetron—Abdominal pain—Epirubicin—testicular cancer	0.000463	0.000716	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—testicular cancer	0.000461	0.000713	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—testicular cancer	0.000449	0.000694	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000443	0.000685	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—testicular cancer	0.000442	0.000685	CcSEcCtD
Palonosetron—Hypersensitivity—Epirubicin—testicular cancer	0.000431	0.000667	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—testicular cancer	0.000428	0.000663	CcSEcCtD
Palonosetron—Body temperature increased—Doxorubicin—testicular cancer	0.000428	0.000663	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—testicular cancer	0.000428	0.000662	CcSEcCtD
Palonosetron—Asthenia—Epirubicin—testicular cancer	0.00042	0.00065	CcSEcCtD
Palonosetron—Pruritus—Epirubicin—testicular cancer	0.000414	0.000641	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—testicular cancer	0.000413	0.00064	CcSEcCtD
Palonosetron—Diarrhoea—Epirubicin—testicular cancer	0.0004	0.00062	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—testicular cancer	0.000399	0.000618	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—testicular cancer	0.000398	0.000615	CcSEcCtD
Palonosetron—Rash—Methotrexate—testicular cancer	0.000394	0.00061	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—testicular cancer	0.000394	0.00061	CcSEcCtD
Palonosetron—Headache—Methotrexate—testicular cancer	0.000392	0.000606	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—testicular cancer	0.000388	0.000601	CcSEcCtD
Palonosetron—Dizziness—Epirubicin—testicular cancer	0.000387	0.000599	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—testicular cancer	0.000383	0.000593	CcSEcCtD
Palonosetron—Vomiting—Epirubicin—testicular cancer	0.000372	0.000576	CcSEcCtD
Palonosetron—Nausea—Methotrexate—testicular cancer	0.000371	0.000575	CcSEcCtD
Palonosetron—Diarrhoea—Doxorubicin—testicular cancer	0.00037	0.000573	CcSEcCtD
Palonosetron—Rash—Epirubicin—testicular cancer	0.000369	0.000571	CcSEcCtD
Palonosetron—Dermatitis—Epirubicin—testicular cancer	0.000369	0.000571	CcSEcCtD
Palonosetron—Headache—Epirubicin—testicular cancer	0.000367	0.000567	CcSEcCtD
Palonosetron—Dizziness—Doxorubicin—testicular cancer	0.000358	0.000554	CcSEcCtD
Palonosetron—Nausea—Epirubicin—testicular cancer	0.000348	0.000538	CcSEcCtD
Palonosetron—Vomiting—Doxorubicin—testicular cancer	0.000344	0.000533	CcSEcCtD
Palonosetron—Rash—Doxorubicin—testicular cancer	0.000341	0.000528	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—testicular cancer	0.000341	0.000528	CcSEcCtD
Palonosetron—Headache—Doxorubicin—testicular cancer	0.000339	0.000525	CcSEcCtD
Palonosetron—Nausea—Doxorubicin—testicular cancer	0.000322	0.000498	CcSEcCtD
